Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
Since its inception early this month, US Merck spinoff Organon has been presenting itself as a company dedicated to women’s health. This focus applies to its Japan business as well, local chief Ryota Sakurai tells Jiho. With no immediate pipeline…
To read the full story
Related Article
- Organon CMO Calls for Balance between Innovation and Access to Longer-Listed Drugs
March 19, 2025
- MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
June 4, 2021
- MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
- MSD Japan to Get Women’s Health Spinoff Organon Up and Running in October: Chief
April 7, 2020
- MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
February 28, 2020
BUSINESS
- Sanofi’s ITP Drug Wayrilz Goes on Sale in Japan
October 21, 2026
- Maruho Secures South Korean Rights to Incyte’s Ruxolitinib Cream
October 21, 2026
- CMIC Turns to AI to Hear Job Applicants in Their Own Words
October 21, 2026
- Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
- Entyvio PIV Trial Links Disease Clearance to 70% Lower UC Complication Risk
October 21, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…